Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 15/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 7/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18537583 | 0.95 | MAPT (0.91) | MAPTPOLBTP53KMT2ASMN1; SMN2 | |
| SCHEMBL17585999 | 0.88 | MAPT (0.78) | MAPTPOLBTP53KMT2ASMN1; SMN2 | |
| SCHEMBL17585985 | 0.87 | SMN1; SMN2 (0.84) | MAPTPOLBTP53KMT2ASMN1; SMN2 | |
| SCHEMBL17585998 | 0.85 | TP53 (0.78) | MAPTPOLBTP53KMT2ASMN1; SMN2 | |
| SCHEMBL17586014 | 0.85 | MAPT (0.73) | MAPTPOLBTP53KMT2ASMN1; SMN2 | |
| SCHEMBL17585986 | 0.84 | MAPT (0.83) | MAPTPOLBTP53KMT2ASMN1; SMN2 | |
| SCHEMBL17586000 | 0.84 | MAPT (0.72) | MAPTPOLBTP53KMT2ASMN1; SMN2 | |
| SCHEMBL14955247 | 0.83 | MAPT (0.80) | MAPTPOLBTP53SMN1; SMN2RXFP1 | |
| SCHEMBL430178 | 0.82 | KMT2A (1.00) | MAPTPOLBTP53KMT2ASMN1; SMN2 | |
| SCHEMBL426129 | 0.82 | MAPT (0.80) | MAPTPOLBTP53KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20160152635-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-9301949-B2 | Thienopyridine derivatives for the treatment and prevention of dengue virus infections | SIGA TECHNOLOGIES, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9301949-B2 | Thienopyridine derivatives for the treatment and prevention of dengue virus infections | SIGA TECHNOLOGIES, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | TTPA, TPMT, SLC19A2 | MAPT 138/4885POLB 4109/4885TP53 3355/4885 |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | TTPA, TPMT, SLC19A2 | MAPT 85/4885POLB 4278/4885TP53 3393/4885 |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | TTPA, TPMT, SLC19A2 | MAPT 85/4885POLB 4278/4885TP53 3393/4885 |
| US-20160152635-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | TTPA, TPMT, SLC19A2 | MAPT 138/4885POLB 4109/4885TP53 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.